Saba Lodhi, MD
Pulmonary Disease · Wenatchee, WANPI 1609071042
Payments from drug & device makers
Across 13 payments — averaging $299.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$2K
- Intuitive Surgical$1K
- Inari Medical, Inc.$235
- Boehringer Ingelheim$36
- ERBE USA Inc$31
- Pulmonx Corporation$12
What the payments were for
- Travel & lodging$1,33876%
- Food & beverage$37722%
- Education$362%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 1 | $2,143 |
| Intuitive Surgical | 8 | $1,438 |
| Inari Medical, Inc. | 1 | $235 |
| Boehringer Ingelheim | 1 | $36 |
| ERBE USA Inc | 1 | $31 |
| Pulmonx Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,894 in reported general payments places this provider in the 75th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 12 | $274,831 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $86,938 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $60,463 |
| NucalaMepolizumab | 16 | $57,604 |
| Spiriva RespimatTiotropium Bromide | 91 | $55,483 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 80 | $37,048 |
| Ambrisentan | 23 | $29,780 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 55 | $26,684 |
| DuleraMometasone/Formoterol | 44 | $14,747 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $10,885 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 80 | $10,518 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $9,089 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $8,521 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $8,252 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $5,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $36 | $93,052157 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Wenatchee
- Balaji LaxmananWenatchee$359K
- Craig KunzWenatchee$46K
- Peter ChenSeattle$2.7M
- Tomasz ZiedalskiEverett$1.6M
- William ParkRenton$1.2M
- Patrick MeehanTacoma$1.1M
- Pradeep SinghSeattle$1.1M
- Moira AitkenSeattle$700K
- Christopher GossSeattle$487K
- Anthony GerbinoSeattle$448K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.